[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @NattaCop TheUrbanFarmer TheUrbanFarmer posts on X about $ocgn, japan, $4503t, approved the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1487028804971155457/interactions)  - X Week XXXXXX +268% - X Month XXXXXX +1,586% - X Months XXXXXX -XX% - X Year XXXXXXX +26% ### Mentions: XX [#](/creator/twitter::1487028804971155457/posts_active)  - X Months XX -XX% - X Year XX +190% ### Followers: XXXXX [#](/creator/twitter::1487028804971155457/followers)  - X Week XXXXX +1.70% - X Month XXXXX +2.70% - X Months XXXXX +14% - X Year XXXXX +17% ### CreatorRank: XXXXXXX [#](/creator/twitter::1487028804971155457/influencer_rank)  ### Social Influence [#](/creator/twitter::1487028804971155457/influence) --- **Social category influence** [countries](/list/countries) [finance](/list/finance) **Social topic influence** [$ocgn](/topic/$ocgn) #1, [japan](/topic/japan) #2404, [$4503t](/topic/$4503t) #2, [approved](/topic/approved), [vice](/topic/vice), [drugs](/topic/drugs), [university of](/topic/university-of), [25m](/topic/25m), [saving](/topic/saving), [mice](/topic/mice) ### Top Social Posts [#](/creator/twitter::1487028804971155457/posts) --- Top posts by engagements in the last XX hours "$ocgn Most will see Phase X for GA in 2026 and shrug. The ones who know GA the therapy and this market understand the gravity of what was just announced. Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the X month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side. Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market. Why Im saying that OCU400 family keeps winning. OCU400 for IRDs OCU410ST for Stargardt" [X Link](https://x.com/NattaCop/status/1977731277647384699) [@NattaCop](/creator/x/NattaCop) 2025-10-13T13:40Z 1214 followers, 5149 engagements "$ocgn like a glove 🍻" [X Link](https://x.com/NattaCop/status/1978937545011388622) [@NattaCop](/creator/x/NattaCop) 2025-10-16T21:34Z 1214 followers, 2736 engagements "Use Korea as the benchmark. Korea deal was about 7.5M upfront with XX percent royalties and Ocugen supplying drug. Scale by market size plus Japan pricing power and the math gets spicy. Spicy" [X Link](https://x.com/NattaCop/status/1979695823043887396) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements "My range for a Japan only license Worst case 25M to 45M upfront Base 50M to 80M upfront Stretch 90M to 120M upfront Royalties XX to XX percent Ocugen likely keeps manufacturing on a cost plus margin. Math check" [X Link](https://x.com/NattaCop/status/1979695827099766893) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements "$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙" [X Link](https://x.com/NattaCop/status/1973779213196083662) [@NattaCop](/creator/x/NattaCop) 2025-10-02T15:56Z 1210 followers, 1869 engagements "$ocgn FDA is opening the door for rare disease CGT (Cell and Gene Therapies) with self controlled trials external controls and registry follow up saving years and millions in development. This directly accelerates OCU400 and OCU410ST bringing them to market at record speed 🍻" [X Link](https://x.com/NattaCop/status/1974228605401203096) [@NattaCop](/creator/x/NattaCop) 2025-10-03T21:42Z 1210 followers, 2833 engagements "$ocgn Did you know mice can model autism biology In those models you see the same direction as humans with RORA turned down in the brain. In a maternal diabetes model where pups reliably show autism like behaviors giving the pregnant dams a RORA agonist (SR1078) led to offspring with a substantial decrease in social and vocalization deficits. Turning up RORA after birth in standard adult models and symptoms like repetitive behaviors drop. In summary RORA shows prevention before birth and symptom control after birth in mice. Its no wonder why autism is on Ocugens radar. They possess a" [X Link](https://x.com/NattaCop/status/1976331633042313318) [@NattaCop](/creator/x/NattaCop) 2025-10-09T16:59Z 1210 followers, 2409 engagements "$ocgn Very interesting Job description specifically: in-plant leadership for manufacturing at Ocugen technical expertise and leadership to Ocugens external manufacturing partners lead technology transfers collaborate across the network This screams a hub and spoke model. Ocugens Malvern facility being the hub that runs the playbook and launch supply. Future partners are the spokes via tech transfer. Yet the only public partner so far is Korea where Ocugen keeps manufacturing control. For India my pick is Bharat Biotech. They have growing CGT capacity so that deal likely trades local" [X Link](https://x.com/NattaCop/status/1974469306542072308) [@NattaCop](/creator/x/NattaCop) 2025-10-04T13:39Z 1214 followers, 2406 engagements "$ocgn breakthrough therapy after therapy continues to get nothing but stellar trial results. This will be the biggest pharma in the world. 💯 📠" [X Link](https://x.com/NattaCop/status/1978576745339961583) [@NattaCop](/creator/x/NattaCop) 2025-10-15T21:40Z 1215 followers, 3872 engagements "$ocgn welcome @drsmusunuri biotech GOAT. May more see just how much brighter youre making the world. 🍻" [X Link](https://x.com/NattaCop/status/1979231819305451544) [@NattaCop](/creator/x/NattaCop) 2025-10-17T17:03Z 1215 followers, 1152 engagements "$ocgn Company Galactic 🤣 ☠" [X Link](https://x.com/NattaCop/status/1979244894087782577) [@NattaCop](/creator/x/NattaCop) 2025-10-17T17:55Z 1215 followers, 1251 engagements "🧵 $ocgn Hot take: stocks push to $XXX will be followed by a Japan partnership announcement and Astellas clearly looks like the partner. Why Astellas" [X Link](https://x.com/NattaCop/status/1979695816655937621) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, 1725 engagements "Astellas is built for retina after the Iveric deal. Huge Japan field force. Real PMDA muscle. No RP conflict of interest. They know pricing and access and they move paperwork fast. How does Japans market look" [X Link](https://x.com/NattaCop/status/1979695818518196503) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements "Quick math check Assume bilateral price in Luxturna class. Treat XXX to XXX patients per year as capacity ramps. That is roughly 15B to 70B in yearly net sales. About 100M to 470M dollars at simple FX. At XX percent royalty that is 20M to 100M a year to Ocugen before any supply margin. Speed" [X Link](https://x.com/NattaCop/status/1979695829998039383) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements "Why Japan can move fast PMDA can accept foreign clinical data under ICH E5. Examples: Luxturna and Zolgensma. No need to redo the world. Our package fits that playbook" [X Link](https://x.com/NattaCop/status/1979695831684112697) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements "Bottom line If Astellas takes Japan the package lands at a 3x to 6x multiple of Korea with double digit royalties and Ocugen keeping the manufacturing lever. This deal is going to be so f**king 🔥😉🤑 Do you Im am long. 🍻" [X Link](https://x.com/NattaCop/status/1979695833311514860) [@NattaCop](/creator/x/NattaCop) 2025-10-18T23:47Z 1214 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@NattaCop TheUrbanFarmer
TheUrbanFarmer posts on X about $ocgn, japan, $4503t, approved the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +268%
- X Month XXXXXX +1,586%
- X Months XXXXXX -XX%
- X Year XXXXXXX +26%
Mentions: XX #
- X Months XX -XX%
- X Year XX +190%
Followers: XXXXX #
- X Week XXXXX +1.70%
- X Month XXXXX +2.70%
- X Months XXXXX +14%
- X Year XXXXX +17%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence countries finance
Social topic influence $ocgn #1, japan #2404, $4503t #2, approved, vice, drugs, university of, 25m, saving, mice
Top Social Posts #
Top posts by engagements in the last XX hours
"$ocgn Most will see Phase X for GA in 2026 and shrug. The ones who know GA the therapy and this market understand the gravity of what was just announced. Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the X month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side. Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market. Why Im saying that OCU400 family keeps winning. OCU400 for IRDs OCU410ST for Stargardt"
X Link @NattaCop 2025-10-13T13:40Z 1214 followers, 5149 engagements
"$ocgn like a glove 🍻"
X Link @NattaCop 2025-10-16T21:34Z 1214 followers, 2736 engagements
"Use Korea as the benchmark. Korea deal was about 7.5M upfront with XX percent royalties and Ocugen supplying drug. Scale by market size plus Japan pricing power and the math gets spicy. Spicy"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements
"My range for a Japan only license Worst case 25M to 45M upfront Base 50M to 80M upfront Stretch 90M to 120M upfront Royalties XX to XX percent Ocugen likely keeps manufacturing on a cost plus margin. Math check"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements
"$ocgn company has nothing but big news to announce for months and years to come. Easiest buy there ever was. 💸 🏦 🚀 🌙"
X Link @NattaCop 2025-10-02T15:56Z 1210 followers, 1869 engagements
"$ocgn FDA is opening the door for rare disease CGT (Cell and Gene Therapies) with self controlled trials external controls and registry follow up saving years and millions in development. This directly accelerates OCU400 and OCU410ST bringing them to market at record speed 🍻"
X Link @NattaCop 2025-10-03T21:42Z 1210 followers, 2833 engagements
"$ocgn Did you know mice can model autism biology In those models you see the same direction as humans with RORA turned down in the brain. In a maternal diabetes model where pups reliably show autism like behaviors giving the pregnant dams a RORA agonist (SR1078) led to offspring with a substantial decrease in social and vocalization deficits. Turning up RORA after birth in standard adult models and symptoms like repetitive behaviors drop. In summary RORA shows prevention before birth and symptom control after birth in mice. Its no wonder why autism is on Ocugens radar. They possess a"
X Link @NattaCop 2025-10-09T16:59Z 1210 followers, 2409 engagements
"$ocgn Very interesting Job description specifically: in-plant leadership for manufacturing at Ocugen technical expertise and leadership to Ocugens external manufacturing partners lead technology transfers collaborate across the network This screams a hub and spoke model. Ocugens Malvern facility being the hub that runs the playbook and launch supply. Future partners are the spokes via tech transfer. Yet the only public partner so far is Korea where Ocugen keeps manufacturing control. For India my pick is Bharat Biotech. They have growing CGT capacity so that deal likely trades local"
X Link @NattaCop 2025-10-04T13:39Z 1214 followers, 2406 engagements
"$ocgn breakthrough therapy after therapy continues to get nothing but stellar trial results. This will be the biggest pharma in the world. 💯 📠"
X Link @NattaCop 2025-10-15T21:40Z 1215 followers, 3872 engagements
"$ocgn welcome @drsmusunuri biotech GOAT. May more see just how much brighter youre making the world. 🍻"
X Link @NattaCop 2025-10-17T17:03Z 1215 followers, 1152 engagements
"$ocgn Company Galactic 🤣 ☠"
X Link @NattaCop 2025-10-17T17:55Z 1215 followers, 1251 engagements
"🧵 $ocgn Hot take: stocks push to $XXX will be followed by a Japan partnership announcement and Astellas clearly looks like the partner. Why Astellas"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, 1725 engagements
"Astellas is built for retina after the Iveric deal. Huge Japan field force. Real PMDA muscle. No RP conflict of interest. They know pricing and access and they move paperwork fast. How does Japans market look"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements
"Quick math check Assume bilateral price in Luxturna class. Treat XXX to XXX patients per year as capacity ramps. That is roughly 15B to 70B in yearly net sales. About 100M to 470M dollars at simple FX. At XX percent royalty that is 20M to 100M a year to Ocugen before any supply margin. Speed"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements
"Why Japan can move fast PMDA can accept foreign clinical data under ICH E5. Examples: Luxturna and Zolgensma. No need to redo the world. Our package fits that playbook"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements
"Bottom line If Astellas takes Japan the package lands at a 3x to 6x multiple of Korea with double digit royalties and Ocugen keeping the manufacturing lever. This deal is going to be so f**king 🔥😉🤑 Do you Im am long. 🍻"
X Link @NattaCop 2025-10-18T23:47Z 1214 followers, XXX engagements